Antidepressants and sexual dysfunction: Mechanisms and clinical implications

Postgraduate Medicine

Volumn 126, Issue 2, 2014, Pages 91-99

  Clayton, Anita H ^a   Croft, Harry A ^b   Handiwala, Lata ^c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b San Antonio Psychiatric Research Center   (United States)

^c Valeant Pharmaceuticals North America LLC   (United States)

Author keywords

Antidepressants; Bupropion; Depression; Selective serotonin reuptake inhibitors; Sexual dysfunction

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; MIRTAZAPINE; NEFAZODONE; VILAZODONE;

ARIZONA SEXUAL EXPERIENCES SCALE; ASSESSMENT OF HUMANS; DEPRESSION; DISEASE ASSOCIATION; DYSPAREUNIA; ERECTILE DYSFUNCTION; GENERAL PRACTITIONER; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); ORGASM DISORDER; PATIENT COMPLIANCE; PREMATURE EJACULATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL AROUSAL DISORDER; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SEXUAL FUNCTIONING QUESTIONNAIRE; SEXUAL SATISFACTION; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; COMPARATIVE EFFECTIVENESS; FEMALE; MALE; PREVALENCE; PSYCHOSEXUAL DISORDER;

ANTIDEPRESSIVE AGENTS; COMPARATIVE EFFECTIVENESS RESEARCH; DEPRESSION; FEMALE; HUMANS; MALE; PREVALENCE; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 84900560846     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2014.03.2744     Document Type: Review

References (62)

1. American Psychiatric Association. Mood disorders. In: American Psychiatric Association Task Force on DSM-IV, ed. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text revision [DSM-IV-TR]. Washington, DC: American Psychiatric Association; 2000: 345-428.
2. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry. 2005; 62(6): 617-627.
3. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23): 3095-3105.
4. Mojtabai R, Olfson M. Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. Health Aff (Millwood). 2011; 30(8): 1434-1442.
5. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999; 281(6): 537-544.
6. Laumann EO, Waite LJ. Sexual dysfunction among older adults: prevalence and risk factors from a nationally representative U.S. probability sample of men and women 57-85 years of age. J Sex Med. 2008; 5(10): 2300-2311.
7. American Psychiatric Association. Sexual and gender identity disorders. In: American Psychiatric Association Task Force on DSM-IV, ed. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text revision [DSM-IV-TR]. Washington, DC: American Psychiatric Association; 2000 : 535-582.
8. Brown AD, Blagg J, Reynolds DS. Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007; 12(17-18): 757-766.
9. Nurnberg HG. An evidence-based review updating the various treatment and management approaches to serotonin reuptake inhibitor-associated sexual dysfunction. Drugs Today (Barc). 2008; 44(2): 147-168.
10. Balon R, Segraves RT. Survey of treatment practices for sexual dysfunction(s) associated with anti-depressants. J Sex Marital Ther. 2008; 34(4): 353-365.
11. Kikuchi T, Uchida H, Suzuki T, Wantanabe K, Kashima H. Patients' attitudes toward side effects of antidepressants: an Internet survey. Eur Arch Psychiatry Clin Neurosci. 2011; 261(2): 103-109.
12. Ashton AK, Rosen RC. Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry. 1998; 59(3): 112-115.
13. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009; 29(3): 259-266.
14. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000; 26(1): 25-40.
15. Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull. 1997; 33(4): 731-745.
16. Rizvi SJ, Yeung NW, Kennedy SH. Instruments to measure sexual dysfunction in community and psychiatric populations. J Psychosom Res. 2011; 70(1): 99-109.
17. Williams K, Reynolds MF. Sexual dysfunction in major depression. CNS Spectr. 2006; 11(8 Suppl 9): 19-23.
18. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001; 62(Suppl 3): 10-21.
19. Montejo-Gonzàlez AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997; 23(3): 176-194.
20. Angst J. Sexual problems in healthy and depressed persons. Int Clin Psychopharmacol. 1998; 13(Suppl 6): S1-S4.
21. Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry. 2006; 67(Suppl 6): 33-37.
22. Kennedy SH, Fulton KA, Bagby RM, Greene AL, Cohen NL, Rafi- Tari S. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry. 2006; 51(4): 234-242.
23. Haberfellner EM. A review of the assessment of antidepressant-induced sexual dysfunction used in randomized, controlled clinical trials. Pharmacopsychiatry. 2007; 40(5): 173-182.
24. Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant- induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 2000; 61(4): 276-281.
25. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002; 63(4): 357-366.
26. Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol. 2010; 24(4): 489-496.
27. Bishop JR, Ellingrod VL, Akroush M, Moline J. The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: possible relationship to oral contraceptives. Hum Psychopharmacol. 2009; 24(3): 207-215.
28. Taylor MJ. Strategies for managing antidepressant-induced sexual dysfunction: a review. Curr Psychiatry Rep. 2006; 8(6): 431-436.
29. Taylor MJ, Rudkin L, Hawton K. Strategies for managing antidepressant- induced sexual dysfunction: systematic review of randomised controlled trials. J Affect Disord. 2005; 88(3): 241-254.
30. Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med. 2007; 4(4 Pt 1): 917-929.
31. Clayton AH, Croft HA, Horrigan JP, et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry. 2006; 67(5): 736-746.
32. Clayton A, Keller A, McGarvey EL. Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord. 2006; 91(1): 27-32.
33. Rosen RC, Lane RM, Menza M. Effect of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999; 19(1): 67-85.
34. Nappi R, Salonia A, Traish AM, et al. Clinical biologic pathophysiologies of women's sexual dysfunction. J Sex Med. 2005; 2(1): 4-25.
35. Clayton AH. Sexual function and dysfunction in women. Psychiatr Clin North Am. 2003; 26(3): 673-682.
36. Basson R, Brotto LA, Laan E, Redmond G, Utian WH. Assessment and management of women's sexual dysfunctions: problematic desire and arousal. J Sex Med. 2005; 2(3): 291-300.
37. Madeo B, Bettica P, Milleri S, et al. The effects of citalopram and fluoxetine on sexual behavior in healthy men: evidence of delayed ejaculation and unaffected sexual desire. A randomized, placebo-controlled, double-blind, double-dummy, parallel group study. J Sex Med. 2008; 5(10): 2431-2441.
38. Suzuki Y, Sawamura K, Someya T. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients. Neuropsychopharmacology. 2006; 31(4): 825-831.
39. Perlis RH, Laje G, Smoller JW, Fava M, Rush AJ, McMahon FJ. Genetic and clinical predictors of sexual dysfunction in citalopram- treated depressed patients. Neuropsychopharmacology. 2009; 34(7): 1819-1828.
40. Bishop JR, Moline J, Ellingrod VL, Schultz SK, Clayton AH. Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology. 2006; 31(10): 2281-2288.
41. Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetineassociated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry. 1993; 54(12): 459-465.
42. Masand PS, Ashton AK, Gupta S, Frank B. Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: a randomized, double-blind, placebo-controlled, parallel-group study. Am J Psychiatry. 2001; 158(5): 805-807.
43. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry. 2002; 14(3): 175-182.
44. DeBattista C, Solvason B, Poirier J, Kendrick E, Loraas E. A placebocontrolled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. J Clin Psychiatry. 2005; 66(7): 844-848.
45. Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol. 2006; 26(5): 482-488.
46. Coleman CC, Cunningham LA, Foster VJ, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry. 1999; 11(4): 205-215.
47. Coleman CC, King BR, Bolden-Watson C, et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther. 2001; 23(7): 1040-1058.
48. Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther. 1999; 21(4): 643-658.
49. Gelenberg AJ, McGahuey C, Laukes C, et al. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry. 2000; 61(5): 356-360.
50. Ozmenler NK, Karlidere T, Bozkurt A, et al. Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors. Hum Psychopharmacol. 2008; 23(4): 321-326.
51. Ravindran LN, Eisfeld BS, Kennedy SH. Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function. J Clin Psychopharmacol. 2008; 28(1): 107-108.
52. Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2012; 66(4): 356-368.
53. Robinson DS, Kajdasz DK, Gallipoli S, Whalen H, Wamil A, Reed CR. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol. 2011; 31(5): 643-646.
54. Khan A, Cutler AJ, Kajdasz DK, et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011; 72(4): 441-447.
55. Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(3): 326-333.
56. Rudkin L, Taylor MJ, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev. 2004(4): CD003382.
57. Ashton AK, Rosen RC. Accommodation to serotonin reuptake inhibitor-induced sexual dysfunction. J Sex Marital Ther. 1998; 24(3): 191-192.
58. Hirschfeld RM. Management of sexual side effects of antidepressant therapy. J Clin Psychiatry. 1999; 60(Suppl 14): 27-30; discussion 31-35.
59. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry. 1995; 152(10): 1514 -1516.
60. Clayton AH, McGarvey EL, Abouesh AI, Pinkerton RC. Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. J Clin Psychiatry. 2001; 62(3): 185-190.
61. Clayton AH, Warnock JK, Kornstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry. 2004; 65(1): 62-67.
62. Zisook S, Rush AJ, Haight BR, Clines DC, Rockett CB. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry. 2006; 59(3): 203-210.